Day: September 14, 2024

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

Written by Customer Service on . Posted in Public Companies.

— Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort — — No New Safety Signals or Added Systemic Safety Concerns Observed — — Data Presented at the European Society for Medical Oncology (ESMO) Congress — NEW YORK, Sept. 14, 2024 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines, announced promising data from the Phase 2 basket trial of IO102-IO103, the company’s lead investigational therapeutic cancer vaccine candidate, in combination with Merck’s (known as MSD outside of the United States and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) (IOB-022/KN-D38)...

Continue reading

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

Written by Customer Service on . Posted in Public Companies.

– Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose– >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy– Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations– GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting– iTeos to host a conference call on Monday, September 16, 2024 at 8:00am ET WATERTOWN, Mass. and GOSSELIES, Belgium, Sept. 14, 2024 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics...

Continue reading

Eco Oro Announces Change in Management Team and Board

Written by Customer Service on . Posted in Public Companies.

VANCOUVER, British Columbia, Sept. 13, 2024 (GLOBE NEWSWIRE) — Eco Oro Minerals Corp. (CSE:EOM) (the “Company”) announced today that Paul Robertson has resigned as Chief Executive Officer of the Company. Eric Tsung, the current Chief Financial Officer of the Company, will assume the role of Chief Executive Officer with immediate effect. Eric will continue in the role of Chief Financial Officer, a position he had held since August 3, 2017. The Company also announced today that Pierre Amariglio has tendered his resignation as member of the Company’s board of directors. Company Profile Eco Oro Minerals Corp. is a publicly-traded company and its arbitration against the Republic of Colombia is its core focus. SOURCE Eco Oro Minerals Corp. For further information: Eco Oro Minerals Corp.Tel: +1 604 682 8212, TF: +1 855 682 8212.

Continue reading

Gran Tierra Energy Inc. Announces Pricing of an Additional $150 Million Aggregate Principal Amount of its 9.500% Senior Secured Amortizing Notes due 2029

Written by Customer Service on . Posted in Public Companies.

CALGARY, Alberta, Sept. 13, 2024 (GLOBE NEWSWIRE) — Gran Tierra Energy Inc. (“Gran Tierra” or the “Company”) (NYSE American:GTE)(TSX:GTE)(LSE:GTE) today announced that it has priced its offering of an additional $150 million aggregate principal amount of its previously issued 9.500% Senior Secured Amortizing Notes due 2029 (the “Notes”) in a private placement to persons reasonably believed to be qualified institutional buyers in the United States pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), to non-U.S. persons in transactions outside the United States pursuant to Regulation S under the Securities Act, and pursuant to certain prospectus exemptions in Canada. Gran Tierra previously had outstanding US$587,590,000 aggregate principal amount of 9.500% Senior Secured Amortizing Notes due...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.